Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
Adoptive immunotherapy with T cells expressing a tumor-specific chimeric T-cell receptor is a promising approach to cancer therapy that has not previously been explored for the treatment of lymphoma… Expand
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.
- D. Shan, J. Ledbetter, O. Press
- Biology, Medicine
- Blood
- 1 March 1998
CD20 is a nonglycosylated 33 to 37 kD phosphoprotein involved in B-cell signaling that subserves important functions in the regulation of B-cell proliferation and differentiation. In addition, this… Expand
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
BACKGROUND
Radiolabeled monoclonal antibodies recognizing B-lymphocyte surface antigens represent a potentially effective new therapy for lymphomas. We assessed the biodistribution, toxicity, and… Expand
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
- D. Shan, J. Ledbetter, O. Press
- Biology, Medicine
- Cancer immunology, immunotherapy : CII
- 23 February 2000
Abstract Anti-CD20 monoclonal antibodies have been successfully employed in the clinical treatment of non-Hodgkin's lymphomas in both unmodified and radiolabeled forms. Previous publications have… Expand
Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.
- O. Press, A. Farr, K. I. Borroz, S. K. Anderson, P. J. Martin
- Biology, Medicine
- Cancer research
- 1 September 1989
Seven murine monoclonal antibodies (MoAbs) recognizing differentiation antigens present on B-lymphocytes were analyzed in preclinical studies for their potential use for antibody-targeted therapy of… Expand
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
- A. Zelenetz, J. Abramson, +27 authors F. Yunus
- Medicine
- Journal of the National Comprehensive Cancer…
- 1 March 2010
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
- M. C. Palanca-Wessels, M. Czuczman, +18 authors F. Morschhauser
- Medicine
- The Lancet. Oncology
- 1 June 2015
BACKGROUND
Patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) have an unfavourable prognosis with few treatment options. Polatuzumab vedotin is an antibody-drug conjugate… Expand
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
- M. Kaminski, A. Zelenetz, +10 authors J. Vose
- Medicine
- Journal of clinical oncology : official journal…
- 1 October 2001
PURPOSE
To evaluate the efficacy and safety of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA) in patients with… Expand
New treatment options have changed the survival of patients with follicular lymphoma.
- R. Fisher, M. Leblanc, O. Press, D. Maloney, J. Unger, T. Miller
- Medicine
- Journal of clinical oncology : official journal…
- 20 November 2005
BACKGROUND
The natural history of follicular lymphoma is believed not to have changed over the last 30 years. Median survivals have ranged from 7 to 10 years, and the disease is considered incurable.… Expand
Evaluation and management of chylous ascites.
- O. Press, N. Press, S. Kaufman
- Medicine
- Annals of internal medicine
- 1 March 1982
Twenty-eight cases of chylous ascites occurring over the past 20 years are analyzed for clinical presentation, cause, yield of diagnostic procedure used, and response to therapy. Malignancies were… Expand